Back to SVRAView Full Landscape
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
3 competitors in Mycobacterium Infections, Nontuberculous
INSMLAI (Liposomal Amikacin for Inhalation) 590 mg
Phase 3INSMALIS
Phase 3INSMLiposomal amikacin for inhalation (LAI)
Phase 2Drug Information
Target Indication
Mycobacterium Infections, Nontuberculous
Clinical Trial
NCT03421743Last updated: 2/13/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts